Who are ANAVEX2-73's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dextromethorphan HBr, Nuedexta (20/10), AVP-786-18, AVP-786-42.63, AVP-786-28.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anavex2-73.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

ANAVEX2-73 — Competitive Intelligence Brief

ANAVEX2-73 (ANAVEX2-73) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sigma-1 receptor agonist. Area: Neurology.

phase 3 Sigma-1 receptor agonist Sigma-1 receptor (S1R) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ANAVEX2-73 (ANAVEX2-73) — Anavex Life Sciences Corp.. ANAVEX2-73 is a sigma-1 receptor agonist that activates neuroprotective pathways to treat neurodegenerative diseases.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ANAVEX2-73 TARGET	ANAVEX2-73	Anavex Life Sciences Corp.	phase 3	Sigma-1 receptor agonist	Sigma-1 receptor (S1R)
Dextromethorphan HBr	Dextromethorphan HBr	Galera Therapeutics, Inc.	marketed	NMDA receptor antagonist; sigma-1 receptor agonist	NMDA receptor; sigma-1 receptor
Nuedexta (20/10)	Nuedexta (20/10)	St. Joseph's Hospital and Medical Center, Phoenix	marketed	Sigma-1 receptor agonist combination	Sigma-1 receptor
AVP-786-18	AVP-786-18	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	Sigma-1 receptor agonist	Sigma-1 receptor
AVP-786-42.63	AVP-786-42.63	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	Sigma-1 receptor agonist	Sigma-1 receptor
AVP-786-28	AVP-786-28	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	Sigma-1 receptor agonist	Sigma-1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sigma-1 receptor agonist class)

Otsuka Pharmaceutical Development & Commercialization, Inc. · 3 drugs in this class
Anavex Life Sciences Corp. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ANAVEX2-73 — Competitive Intelligence Brief. https://druglandscape.com/ci/anavex2-73. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab